Ken Griffin Citadel Advisors
Ken Griffin founded Citadel, one of the world’s largest and most successful hedge funds. Starting his trading career from his Harvard dorm room at a young age, Griffin quickly developed a keen sense for markets and built Citadel into a global powerhouse with billions in assets under management. Known for his quantitative and technology-driven strategies, Griffin has also made headlines for significant philanthropic contributions, supporting causes in education, the arts, and public institutions. Over the years, he has earned recognition as one of the preeminent figures in modern finance.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$772M |
| 2 |
Eli Lilly
LLY
|
+$337M |
| 3 |
lululemon athletica
LULU
|
+$301M |
| 4 |
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
|
+$297M |
| 5 |
ResMed
RMD
|
+$273M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$576M |
| 2 |
AT&T
T
|
+$476M |
| 3 |
PNC Financial Services
PNC
|
+$393M |
| 4 |
Fortive
FTV
|
+$389M |
| 5 |
Accenture
ACN
|
+$374M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 2.83% |
| 2 | Technology | 2.79% |
| 3 | Financials | 2.29% |
| 4 | Consumer Discretionary | 1.93% |
| 5 | Industrials | 1.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
KORE
11901
DELISTED
KORE Group Holdings
KORE
| $45K | ﹤0.01% |
2,953
-10,809
| -79% | -$241K |
|
11902
KULR Technology Group
KULR
$122M
| $45K | ﹤0.01% |
3,631
-8,981
| -71% | -$120K |
|
11903
CALL
Precipio
PRPO
$42M
| $45K | ﹤0.01% |
2,100
+430
| +26% | +$9.75K |
|
|
VRNA
11904
DELISTED
Verona Pharma
VRNA
| $45K | ﹤0.01% |
+10,749
| New | +$46K |
|
11905
Westwater Resources
WWR
$72.7M
| $45K | ﹤0.01% |
41,765
-159,459
| -79% | -$208K |
|
|
OMGA
11906
PUT
DELISTED
Omega Therapeutics, Inc. Common Stock
OMGA
| $45K | ﹤0.01% |
+11,900
| New | +$44.3K |
|
|
BIOC
11907
DELISTED
Biocept, Inc.
BIOC
| $45K | ﹤0.01% |
1,605
+971
| +153% | +$44.2K |
|
11908
Avalo Therapeutics
AVTX
$1.05B
| $44K | ﹤0.01% |
31
+21
| +210% | +$28.1K |
|
11909
CALL
Flotek Industries
FTK
$1.3B
| $44K | ﹤0.01% |
7,400
+2,867
| +63% | +$21.6K |
|
11910
PUT
StealthGas
GASS
$352M
| $44K | ﹤0.01% |
+13,800
| New | +$38.5K |
|
11911
Heart Test Laboratories
HSCS
$8.03M
| $44K | ﹤0.01% |
+234
| New | +$45.2K |
|
11912
CALL
Skillsoft
SKIL
$74.2M
| $44K | ﹤0.01% |
620
-1,300
| -68% | -$134K |
|
11913
Solid Biosciences
SLDB
$986M
| $44K | ﹤0.01% |
4,683
+3,992
| +578% | +$41.5K |
|
11914
X4 Pharmaceuticals
XFOR
$418M
| $44K | ﹤0.01% |
1,508
-342
| -18% | -$13K |
|
|
INFI
11915
CALL
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
| $44K | ﹤0.01% |
68,800
+12,000
| +21% | +$9.21K |
|
|
RKLY
11916
CALL
DELISTED
Rockley Photonics Holdings Limited
RKLY
| $44K | ﹤0.01% |
20,100
-50,700
| -72% | -$155K |
|
|
FRMM
11917
Forum Markets
FRMM
$80.4M
| $43K | ﹤0.01% |
13
+5
| +63% | +$28.7K |
|
11918
CALL
Ceragon Networks
CRNT
$200M
| $43K | ﹤0.01% |
16,900
-5,100
| -23% | -$9.73K |
|
11919
Heritage Global
HGBL
$37.8M
| $43K | ﹤0.01% |
28,653
+6,719
| +31% | +$8.23K |
|
|
IMMP
11920
Immutep
IMMP
$56M
| $43K | ﹤0.01% |
21,011
+2,281
| +12% | +$5.64K |
|
11921
iSpecimen
ISPC
$3.23M
| $43K | ﹤0.01% |
+25
| New | +$61.2K |
|
|
JG
11922
Aurora Mobile
JG
$34.2M
| $43K | ﹤0.01% |
2,013
-89
| -4% | -$1.8K |
|
11923
Jowell Global
JWEL
$7.34M
| $43K | ﹤0.01% |
1,038
+108
| +12% | +$4.11K |
|
11924
CALL
Odyssey Marine Exploration
OMEX
$52.9M
| $43K | ﹤0.01% |
+12,700
| New | +$61.3K |
|
11925
Palladyne AI Corp Warrants
PDYNW
$188K
| $43K | ﹤0.01% |
79,353
-1,956
| -2% | -$1.3K |
|
Similar funds
Ken Griffin's Q2 2022 Portfolio in Review
As of Q2 2022, Ken Griffin held 14,957 positions worth $390B, down 20% from $484B the previous quarter. Its ten largest holdings account for 28% of the portfolio.
Ken Griffin's Q2 2022 filing shows 1,520 new, 5,503 increased, 5,522 reduced and 2,191 closed positions. Its largest new stake was ResMed: 1,280,595 shares worth $268M. The largest sale was State Street SPDR S&P 500 ETF Trust, an estimated $576M.
By sector, the portfolio is most concentrated in Healthcare at 2.8% of assets, up from 2.4% a quarter earlier, followed by Technology and Financials.
- Ken Griffin's largest Q2 2022 buy was ResMed: 1,280,595 shares worth $268M.
- Ken Griffin added most to Meta Platforms (Facebook) in Q2 2022, an estimated $772M increase.
- Ken Griffin's biggest Q2 2022 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $576M.
- Ken Griffin fully exited Vanguard Morningstar Small-Cap ETF in Q2 2022, selling an estimated $184M.
- Ken Griffin's ten largest holdings make up 28% of its $390B portfolio in Q2 2022.
- Ken Griffin opened 1,520 new positions and closed 2,191 in Q2 2022.
- Ken Griffin's portfolio value fell 20% quarter-over-quarter to $390B.
Based on Citadel Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.